● Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Condition: Endometrial Cancer · Sponsor: AstraZeneca

PhasePhase 3

Planned participants600

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (250)

Research Site	Tucson, Arizona, United States	Withdrawn
Research Site	Little Rock, Arkansas, United States	Recruiting
Research Site	Duarte, California, United States	Not Yet Recruiting
Research Site	Irvine, California, United States	Not Yet Recruiting
Research Site	La Jolla, California, United States	Recruiting
Research Site	Palo Alto, California, United States	Withdrawn
Research Site	San Francisco, California, United States	Suspended
Research Site	Sylmar, California, United States	Withdrawn
Research Site	Fort Myers, Florida, United States	Recruiting
Research Site	Miami Beach, Florida, United States	Recruiting
Research Site	Orlando, Florida, United States	Not Yet Recruiting
Research Site	St. Petersburg, Florida, United States	Recruiting

+ 238 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06989112